Brief: Vivani Medical Announces Positive Preclinical Weight Loss Data for NPM-139 Semaglutide Implant, with Potential for Once-Yearly Dosing
26/03/2025 11:38
March 26 (Reuters) - Vivani Medical Inc VANI.O: VIVANI MEDICAL ANNOUNCES POSITIVE PRECLINICAL WEIGHT LOSS DATA FOR NPM-139 SEMAGLUTIDE IMPLANT, WITH POTENTIAL FOR ONCE-YEARLY DOSING VIVANI MEDICAL INC - NPM-139 TREATMENT RESULTS IN NEARLY 20% PLACEBO-ADJUSTED WEIGHT LOSS VIVANI MEDICAL INC - NANOPORTAL TECHNOLOGY SUCCESSFULLY DELIVERS SEMAGLUTIDE IN PRECLINICAL STUDY Source text: ID:nGNXqck2D Further company coverage: VANI.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vivani Medical
See all newsVivani Medical Q2 net loss narrows as expenses fall
Vivani Medical Inc reports results for the quarter ended June 30 - Earnings Summary
Vivani Medical Inc expected to post a loss of 8 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Vera Therapeutics, Vera Therapeutics, Nvidia
U.S. STOCKS ON THE MOVE-Revolution Medicines, Vivani Medical, Nvidia